Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against Escherichia coli
Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the...
Saved in:
| Published in | PeerJ (San Francisco, CA) Vol. 5; p. e3168 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
PeerJ, Inc
26.04.2017
PeerJ Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2167-8359 2167-8359 |
| DOI | 10.7717/peerj.3168 |
Cover
| Abstract | Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone – PQQ4R), against
Escherichia coli,
by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in
E. coli
reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the
E. coli
inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against
E. coli
and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. |
|---|---|
| AbstractList | Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone – PQQ4R), against
Escherichia coli,
by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in
E. coli
reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the
E. coli
inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against
E. coli
and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone - PQQ4R), against Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in E. coli reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the E. coli inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against E. coli and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux.Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone - PQQ4R), against Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in E. coli reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the E. coli inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against E. coli and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone – PQQ4R), against Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in E. coli reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the E. coli inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against E. coli and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone - PQQ4R), against by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone – PQQ4R), against Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ). The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with antibiotics known to be subject to efflux in E. coli reducing their MIC in correlation with the inhibition of their efflux. Real-time fluorometry assays demonstrated that PQQ4R at sub-inhibitory concentrations promote the intracellular accumulation of ethidium bromide inhibiting its efflux similarly to PAβN or CPZ, well-known and described efflux pump inhibitors for Gram-negative bacteria and whose clinical usage is limited by their levels of toxicity at clinical and bacteriological effective concentrations. The time-kill studies showed that PQQ4R, at bactericidal concentrations, has a rapid antimicrobial activity associated with a fast decrease of the intracellular ATP levels. The results also indicated that the mode of action of PQQ4R involves the destabilization of the E. coli inner membrane potential and ATP production impairment, ultimately leading to efflux pump inhibition by interference with the energy required by the efflux systems. At bactericidal concentrations, membrane permeabilization increases and finally ATP is totally depleted leading to cell death. Since drug resistance mediated by the activity of efflux pumps depends largely on the proton motive force (PMF), dissipaters of PMF such as PQQ4R, can be regarded as future adjuvants of conventional therapy against E. coli and other Gram-negative bacteria, especially their multidrug resistant forms. Their major limitation is the high toxicity for human cells at the concentrations needed to be effective against bacteria. Their future molecular optimization to improve the efflux inhibitory properties and reduce relative toxicity will optimize their potential for clinical usage against multi-drug resistant bacterial infections due to efflux. |
| ArticleNumber | e3168 |
| Author | Manfroni, Giuseppe Sabatini, Stefano Couto, Isabel Tabarrini, Oriana Fernandes, Laura Viveiros, Miguel Machado, Diana Costa, Sofia S. Cannalire, Rolando |
| Author_xml | – sequence: 1 givenname: Diana surname: Machado fullname: Machado, Diana organization: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, Portugal – sequence: 2 givenname: Laura surname: Fernandes fullname: Fernandes, Laura organization: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, Portugal, Laboratório de Diagnóstico Molecular Veterinário GeneVet, Algés, Portugal – sequence: 3 givenname: Sofia S. surname: Costa fullname: Costa, Sofia S. organization: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, Portugal – sequence: 4 givenname: Rolando surname: Cannalire fullname: Cannalire, Rolando organization: Department of Pharmaceutical Sciences, Universitá degli Studi di Perugia, Perugia, Italy – sequence: 5 givenname: Giuseppe surname: Manfroni fullname: Manfroni, Giuseppe organization: Department of Pharmaceutical Sciences, Universitá degli Studi di Perugia, Perugia, Italy – sequence: 6 givenname: Oriana surname: Tabarrini fullname: Tabarrini, Oriana organization: Department of Pharmaceutical Sciences, Universitá degli Studi di Perugia, Perugia, Italy – sequence: 7 givenname: Isabel surname: Couto fullname: Couto, Isabel organization: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, Portugal – sequence: 8 givenname: Stefano surname: Sabatini fullname: Sabatini, Stefano organization: Department of Pharmaceutical Sciences, Universitá degli Studi di Perugia, Perugia, Italy – sequence: 9 givenname: Miguel surname: Viveiros fullname: Viveiros, Miguel organization: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Lisboa, Portugal |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28516003$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1rFTEQhoNUbK298QfIgjdS2JqPzW72RpDSaqGiFcXLkI_J2Rz2JKfJrth_b7anlbaYmwyTd56ZycxLtBdiAIReE3zSdaR7vwVI6xNGWvEMHVDSdrVgvN97YO-jo5zXuBxBWyzYC7RPBSctxuwA_foSLVTRVcpMPobFmgaoaL0dINyM17MPcfQBKnBunP9UPgxe-ymm6tvVVfO9UivlQ56qs2wGSN4MXlWmRLxCz50aMxzd3Yfo5_nZj9PP9eXXTxenHy9r07B2qpWmjtOeY8KYda0SzlpKW8p0Q3BrwXGHCdWca9aDsLpttOm6ntIGC-WEYofoYse1Ua3lNvmNSjcyKi9vHTGtpEqTNyPIvtNCNdQyYURDO6sFdr2woIvTMUcK68OOtZ31BqyBMCU1PoI-fgl-kKv4W_KGsYbyAnh3B0jxeoY8yY3PBsZRBYhzlqTHpRvat0uut0-k6zinUL6qqDhjZOm_qN48rOhfKffzKwK8E5gUc07gpPGTWiZZCvSjJFguWyJvt0QuW1JCjp-E3FP_I_4LINe9ug |
| CitedBy_id | crossref_primary_10_1016_j_scitotenv_2023_167281 crossref_primary_10_1371_journal_ppat_1012121 crossref_primary_10_1128_AEM_00155_21 crossref_primary_10_1080_07391102_2023_2175381 crossref_primary_10_1016_j_jiac_2022_01_003 crossref_primary_10_3390_antibiotics11040497 crossref_primary_10_3390_antibiotics10111378 crossref_primary_10_1002_med_21591 crossref_primary_10_2217_fmb_2018_0110 crossref_primary_10_1128_spectrum_02024_22 crossref_primary_10_3389_fmicb_2019_02153 crossref_primary_10_1080_17460441_2023_2213886 crossref_primary_10_3390_molecules26226996 crossref_primary_10_1021_acsinfecdis_9b00041 crossref_primary_10_1128_spectrum_04876_22 crossref_primary_10_1016_j_ejmech_2023_115148 crossref_primary_10_3389_fmicb_2019_00092 crossref_primary_10_1016_j_jprot_2018_05_006 crossref_primary_10_33073_pjm_2020_007 crossref_primary_10_1099_jmm_0_000741 crossref_primary_10_2217_fmb_2019_0296 crossref_primary_10_1016_j_jgar_2020_03_019 crossref_primary_10_3390_antibiotics13070628 crossref_primary_10_1002_pro_3355 crossref_primary_10_1038_s41598_021_00249_y crossref_primary_10_3389_fmicb_2019_02319 crossref_primary_10_1128_Spectrum_00951_21 crossref_primary_10_1021_acsinfecdis_1c00281 crossref_primary_10_1093_jac_dkab388 crossref_primary_10_3390_pharmaceutics11050203 crossref_primary_10_4103_ijmr_IJMR_2079_17 crossref_primary_10_1016_j_bioorg_2020_104225 crossref_primary_10_1038_s42004_025_01477_3 crossref_primary_10_3389_fmicb_2018_01301 crossref_primary_10_3889_oamjms_2022_11081 |
| Cites_doi | 10.1128/AAC.45.1.105-116.2001 10.1128/AAC.49.8.3578-3582.2005 10.1080/1062936X.2015.1106581 10.1021/jm200370y 10.3389/fmicb.2015.00587 10.1016/j.bbabio.2014.03.017 10.1016/j.ijantimicag.2007.12.015 10.1371/journal.pone.0000365 10.1128/JB.155.2.531-540.1983 10.1128/CMR.19.2.382-402.2006 10.1128/AAC.01866-13 10.1371/journal.pone.0060666 10.1021/acsinfecdis.5b00052 10.1111/j.1574-6976.2011.00290.x 10.1016/j.bmcl.2003.07.030 10.1016/j.chembiol.2013.07.006 10.7717/peerj.1987 10.1046/j.1432-1327.2000.01606.x 10.1128/AAC.47.9.3030-3033.2003 10.1016/j.ejmech.2011.05.013 10.1038/nrmicro1098 10.1128/jb.178.1.306-308.1996 10.1038/nrmicro1464 10.1007/978-1-62703-290-2_7 10.1093/jac/dki445 10.1016/j.bbapap.2008.10.004 10.1128/JB.02456-14 10.3389/fmicb.2015.00377 10.1021/acs.jpcb.5b11942 10.2174/1874285801307010083 10.3389/fmicb.2015.00330 10.1038/nature13205 10.1007/978-1-60327-279-7_12 10.1371/journal.pone.0064518 10.1021/jm400262a 10.1073/pnas.0500469102 10.2165/11317030-000000000-00000 10.1371/journal.pone.0149326 10.1128/AAC.03283-14 10.1128/AAC.01995-15 |
| ContentType | Journal Article |
| Copyright | 2017 Machado et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Machado et al. 2017 Machado et al. |
| Copyright_xml | – notice: 2017 Machado et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Machado et al. 2017 Machado et al. |
| DBID | AAYXX CITATION NPM 3V. 7XB 88I 8FE 8FH 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M2P M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.7717/peerj.3168 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2167-8359 |
| ExternalDocumentID | oai_doaj_org_article_97b8a42d38c8427db80f98deba42f3f1 PMC5433425 28516003 10_7717_peerj_3168 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Fundação para a Ciência e a Tecnologia (FCT), Portugal grantid: PTDC/BIA-MIC/121859/2010; GHTM-UID/Multi/04413/2013; SFRH/BPD/100688/2014; SFRH/BPD/97508/2013 |
| GroupedDBID | 53G 5VS 88I 8FE 8FH AAFWJ AAYXX ABUWG ADBBV ADRAZ AENEX AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO GNUQQ GROUPED_DOAJ GX1 H13 HCIFZ HYE IAO IEA IHR IHW ITC KQ8 LK8 M2P M48 M7P M~E OK1 PHGZM PHGZT PIMPY PQQKQ PROAC RPM W2D YAO ECGQY NPM PQGLB 3V. 7XB 8FK PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c436t-ab2f52950133df6a8fdd22623b4106def5f012b55b39e8db64bc77922408af8a3 |
| IEDL.DBID | M48 |
| ISSN | 2167-8359 |
| IngestDate | Wed Aug 27 00:59:57 EDT 2025 Thu Aug 21 18:36:23 EDT 2025 Thu Sep 04 22:30:12 EDT 2025 Fri Jul 25 11:59:07 EDT 2025 Mon Jul 21 05:48:31 EDT 2025 Tue Jul 01 04:26:58 EDT 2025 Thu Apr 24 22:57:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Antibiotic synergism Efflux pumps AcrAB Efflux inhibitor Membrane permeability RND ATP production impairment Membrane potential |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c436t-ab2f52950133df6a8fdd22623b4106def5f012b55b39e8db64bc77922408af8a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.7717/peerj.3168 |
| PMID | 28516003 |
| PQID | 1953314106 |
| PQPubID | 2045935 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_97b8a42d38c8427db80f98deba42f3f1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433425 proquest_miscellaneous_1900122961 proquest_journals_1953314106 pubmed_primary_28516003 crossref_citationtrail_10_7717_peerj_3168 crossref_primary_10_7717_peerj_3168 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-04-26 |
| PublicationDateYYYYMMDD | 2017-04-26 |
| PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Diego – name: San Francisco, USA |
| PublicationTitle | PeerJ (San Francisco, CA) |
| PublicationTitleAlternate | PeerJ |
| PublicationYear | 2017 |
| Publisher | PeerJ, Inc PeerJ Inc |
| Publisher_xml | – name: PeerJ, Inc – name: PeerJ Inc |
| References | Thorsing (10.7717/peerj.3168/ref-36) 2013; 8 Du (10.7717/peerj.3168/ref-8) 2014; 509 Piddock (10.7717/peerj.3168/ref-29) 2007; 4 Sabatini (10.7717/peerj.3168/ref-32) 2013; 56 Herbel (10.7717/peerj.3168/ref-13) 2016; 4 Machado (10.7717/peerj.3168/ref-19) 2016; 11 Nikaido (10.7717/peerj.3168/ref-22) 2012; 36 Machado (10.7717/peerj.3168/ref-18) 2015; 1 O’Brien (10.7717/peerj.3168/ref-25) 2000; 267 Viveiros (10.7717/peerj.3168/ref-41) 2007; 2 Anes (10.7717/peerj.3168/ref-1) 2015; 6 GraphPad Software (10.7717/peerj.3168/ref-12) 2016 Viveiros (10.7717/peerj.3168/ref-40) 2008; 31 Bohnert (10.7717/peerj.3168/ref-2) 2013; 7 Misra (10.7717/peerj.3168/ref-21) 2015; 197 Farha (10.7717/peerj.3168/ref-10) 2013; 20 Viveiros (10.7717/peerj.3168/ref-39) 2005; 49 Watkins (10.7717/peerj.3168/ref-43) 2003; 13 Zuo (10.7717/peerj.3168/ref-47) 2016; 120 Coelho (10.7717/peerj.3168/ref-7) 2015; 6 Venter (10.7717/peerj.3168/ref-38) 2015; 6 Schurig-Briccio (10.7717/peerj.3168/ref-35) 2014; 1837 Lomovskaya (10.7717/peerj.3168/ref-17) 2001; 45 Salih (10.7717/peerj.3168/ref-34) 1991; 28 Viveiros (10.7717/peerj.3168/ref-42) 2010 Okusu (10.7717/peerj.3168/ref-26) 1996; 178 Brogden (10.7717/peerj.3168/ref-4) 2005; 3 Chan (10.7717/peerj.3168/ref-5) 2013; 979 George (10.7717/peerj.3168/ref-11) 1983; 155 Opperman (10.7717/peerj.3168/ref-27) 2014; 58 Piddock (10.7717/peerj.3168/ref-28) 2006; 19 Clinical and Laboratory Standards Institute (10.7717/peerj.3168/ref-6) 2014 European Centre for Disease Prevention and Control (10.7717/peerj.3168/ref-9) 2015 Nikaido (10.7717/peerj.3168/ref-23) 2009; 1794 Yilmaz (10.7717/peerj.3168/ref-46) 2015; 26 Bohnert (10.7717/peerj.3168/ref-3) 2016; 60 Li (10.7717/peerj.3168/ref-16) 2009; 69 Sabatini (10.7717/peerj.3168/ref-33) 2011; 54 Weinstein (10.7717/peerj.3168/ref-44) 2005; 122 World Health Organization (10.7717/peerj.3168/ref-45) 2014 Pluta (10.7717/peerj.3168/ref-31) 2011; 46 Kern (10.7717/peerj.3168/ref-14) 2006; 57 Nishino (10.7717/peerj.3168/ref-24) 2003; 47 Machado (10.7717/peerj.3168/ref-20) 2011; 25 Pillai (10.7717/peerj.3168/ref-30) 2005 Vargiu (10.7717/peerj.3168/ref-37) 2014; 58 Lamers (10.7717/peerj.3168/ref-15) 2013; 8 |
| References_xml | – volume: 45 start-page: 105 year: 2001 ident: 10.7717/peerj.3168/ref-17 article-title: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.45.1.105-116.2001 – volume: 49 start-page: 3578 year: 2005 ident: 10.7717/peerj.3168/ref-39 article-title: Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.49.8.3578-3582.2005 – volume: 26 start-page: 853 year: 2015 ident: 10.7717/peerj.3168/ref-46 article-title: Binding site feature description of 2-substituted benzothiazoles as potential AcrAB-TolC efflux pump inhibitors in E. coli publication-title: SAR and QSAR in Environmental Research doi: 10.1080/1062936X.2015.1106581 – volume: 54 start-page: 5722 year: 2011 ident: 10.7717/peerj.3168/ref-33 article-title: Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump publication-title: Journal of Medicinal Chemistry doi: 10.1021/jm200370y – volume: 6 year: 2015 ident: 10.7717/peerj.3168/ref-1 article-title: The ins and outs of RND efflux pumps in Escherichia coli publication-title: Frontiers in Microbiology doi: 10.3389/fmicb.2015.00587 – volume: 1837 start-page: 954 year: 2014 ident: 10.7717/peerj.3168/ref-35 article-title: Characterization of the type 2 NADH: menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines publication-title: Biochimica et Biophysica Acta (BBA)-Bioenergetics doi: 10.1016/j.bbabio.2014.03.017 – volume: 31 start-page: 458 year: 2008 ident: 10.7717/peerj.3168/ref-40 article-title: Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method publication-title: International Journal of Antimicrobial Agents doi: 10.1016/j.ijantimicag.2007.12.015 – volume: 2 start-page: e365 year: 2007 ident: 10.7717/peerj.3168/ref-41 article-title: Antibiotic stress, genetic response and altered permeability of E. coli publication-title: PLOS ONE doi: 10.1371/journal.pone.0000365 – volume: 155 start-page: 531 year: 1983 ident: 10.7717/peerj.3168/ref-11 article-title: Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline publication-title: Journal of Bacteriology doi: 10.1128/JB.155.2.531-540.1983 – volume: 19 start-page: 382 year: 2006 ident: 10.7717/peerj.3168/ref-28 article-title: Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria publication-title: Clinical Microbiology Reviews doi: 10.1128/CMR.19.2.382-402.2006 – volume-title: 2014 summary. WHO/HSE/PED/AIP/2014.2 year: 2014 ident: 10.7717/peerj.3168/ref-45 article-title: Antimicrobial resistance global report on surveillance – volume: 58 start-page: 722 year: 2014 ident: 10.7717/peerj.3168/ref-27 article-title: Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.01866-13 – volume: 8 start-page: e60666 year: 2013 ident: 10.7717/peerj.3168/ref-15 article-title: The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of Gram-negative bacteria publication-title: PLOS ONE doi: 10.1371/journal.pone.0060666 – start-page: 365 volume-title: Antibiotics in laboratory medicine year: 2005 ident: 10.7717/peerj.3168/ref-30 article-title: Antimicrobial combinations – volume: 1 start-page: 593 year: 2015 ident: 10.7717/peerj.3168/ref-18 article-title: The boosting effect of 2-phenylquinoline efflux inhibitors in combination with macrolides against Mycobacterium smegmatis and Mycobacterium avium publication-title: ACS Infectious Diseases doi: 10.1021/acsinfecdis.5b00052 – volume: 36 start-page: 340 year: 2012 ident: 10.7717/peerj.3168/ref-22 article-title: Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria publication-title: FEMS Microbiology Reviews doi: 10.1111/j.1574-6976.2011.00290.x – volume: 13 start-page: 4241 year: 2003 ident: 10.7717/peerj.3168/ref-43 article-title: The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors publication-title: Bioorganic & Medicinal Chemistry Letters doi: 10.1016/j.bmcl.2003.07.030 – volume: 20 start-page: 1168 year: 2013 ident: 10.7717/peerj.3168/ref-10 article-title: Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus publication-title: Chemistry & Biology doi: 10.1016/j.chembiol.2013.07.006 – volume: 4 start-page: e1987 year: 2016 ident: 10.7717/peerj.3168/ref-13 article-title: Mode of action and membrane specificity of the antimicrobial peptide snakin-2 publication-title: PeerJ doi: 10.7717/peerj.1987 – volume: 267 start-page: 5421 year: 2000 ident: 10.7717/peerj.3168/ref-25 article-title: Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity publication-title: European Journal of Biochemistry doi: 10.1046/j.1432-1327.2000.01606.x – volume: 47 start-page: 3030 year: 2003 ident: 10.7717/peerj.3168/ref-24 article-title: Roles of TolC-dependent multidrug transporters of Escherichia coli in resistance to β-lactams publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.47.9.3030-3033.2003 – volume: 46 start-page: 3179 year: 2011 ident: 10.7717/peerj.3168/ref-31 article-title: Recent progress in biological activities of synthesized phenothiazines publication-title: European Journal of Medicinal Chemistry doi: 10.1016/j.ejmech.2011.05.013 – volume-title: Antimicrobial resistance and healthcare-associated infections year: 2015 ident: 10.7717/peerj.3168/ref-9 article-title: Annual epidemiological report 2014 – volume: 28 start-page: 491 year: 1991 ident: 10.7717/peerj.3168/ref-34 article-title: Calmodulin-like activity in mycobacteria publication-title: Indian Journal of Biochemistry and Biophysics – volume: 3 start-page: 238 year: 2005 ident: 10.7717/peerj.3168/ref-4 article-title: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? publication-title: Nature Reviews Microbiology doi: 10.1038/nrmicro1098 – volume-title: CLSI document M100-S24 year: 2014 ident: 10.7717/peerj.3168/ref-6 article-title: Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement – volume: 178 start-page: 306 year: 1996 ident: 10.7717/peerj.3168/ref-26 article-title: AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants publication-title: Journal of Bacteriology doi: 10.1128/jb.178.1.306-308.1996 – volume: 25 start-page: 769 year: 2011 ident: 10.7717/peerj.3168/ref-20 article-title: Biological activity of twenty-three hydantion derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349 publication-title: In Vivo – volume: 4 start-page: 629 year: 2007 ident: 10.7717/peerj.3168/ref-29 article-title: Multidrug-resistance efflux pumps—not just for resistance publication-title: Nature Reviews Microbiology doi: 10.1038/nrmicro1464 – volume: 979 start-page: 65 year: 2013 ident: 10.7717/peerj.3168/ref-5 article-title: Detection of necrosis by release of lactate dehydrogenase activity publication-title: Immune Homeostasis: Methods and Protocols doi: 10.1007/978-1-62703-290-2_7 – volume: 57 start-page: 339 year: 2006 ident: 10.7717/peerj.3168/ref-14 article-title: Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dki445 – volume: 1794 start-page: 769 year: 2009 ident: 10.7717/peerj.3168/ref-23 article-title: Mechanisms of RND multidrug efflux pumps publication-title: Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics doi: 10.1016/j.bbapap.2008.10.004 – volume: 197 start-page: 2479 year: 2015 ident: 10.7717/peerj.3168/ref-21 article-title: Importance of real-time assays to distinguish multidrug efflux pump inhibiting and outer membrane destabilizing activities in Escherichia coli publication-title: Journal of Bacteriology doi: 10.1128/JB.02456-14 – volume: 6 year: 2015 ident: 10.7717/peerj.3168/ref-38 article-title: RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition publication-title: Frontiers in Microbiology doi: 10.3389/fmicb.2015.00377 – volume: 120 start-page: 2145 year: 2016 ident: 10.7717/peerj.3168/ref-47 article-title: Insights into the inhibitory mechanism of D13-9001 to the multidrug transporter AcrB through molecular dynamics simulations publication-title: The Journal of Physical Chemistry B doi: 10.1021/acs.jpcb.5b11942 – volume: 7 start-page: 83 year: 2013 ident: 10.7717/peerj.3168/ref-2 article-title: Pimozine inhibits the AcrAB-TolC efflux pump in Escherichia coli publication-title: The Open Microbiology Journal doi: 10.2174/1874285801307010083 – volume: 6 year: 2015 ident: 10.7717/peerj.3168/ref-7 article-title: Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil publication-title: Frontiers in Microbiology doi: 10.3389/fmicb.2015.00330 – volume: 509 start-page: 512 year: 2014 ident: 10.7717/peerj.3168/ref-8 article-title: Structure of the AcrAB-TolC multidrug efflux pump publication-title: Nature doi: 10.1038/nature13205 – start-page: 159 volume-title: Antibiotic resistance protocols year: 2010 ident: 10.7717/peerj.3168/ref-42 article-title: Evaluation of efflux activity of bacteria by a semi-automated fluorometric system doi: 10.1007/978-1-60327-279-7_12 – volume: 8 start-page: e64518 year: 2013 ident: 10.7717/peerj.3168/ref-36 article-title: Thioridazine induces major changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus aureus USA300 publication-title: PLOS ONE doi: 10.1371/journal.pone.0064518 – year: 2016 ident: 10.7717/peerj.3168/ref-12 article-title: QuickCalcs – volume: 56 start-page: 4975 year: 2013 ident: 10.7717/peerj.3168/ref-32 article-title: Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance publication-title: Journal of Medicinal Chemistry doi: 10.1021/jm400262a – volume: 122 start-page: 4548 year: 2005 ident: 10.7717/peerj.3168/ref-44 article-title: Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.0500469102 – volume: 69 start-page: 1555 year: 2009 ident: 10.7717/peerj.3168/ref-16 article-title: Efflux-mediated drug resistance in bacteria: an update publication-title: Drugs doi: 10.2165/11317030-000000000-00000 – volume: 11 start-page: e0149326 year: 2016 ident: 10.7717/peerj.3168/ref-19 article-title: Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant Mycobacterium tuberculosis publication-title: PLOS ONE doi: 10.1371/journal.pone.0149326 – volume: 58 start-page: 6224 year: 2014 ident: 10.7717/peerj.3168/ref-37 article-title: Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.03283-14 – volume: 60 start-page: 1974 year: 2016 ident: 10.7717/peerj.3168/ref-3 article-title: Novel piperazine arylideimidazolones inhibit the AcrAB-TolC pump in Escherichia coli and simultaneously act as fluorescent membrane probes in a combined real-time influx and efflux assay publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.01995-15 |
| SSID | ssj0000826083 |
| Score | 2.2593246 |
| Snippet | Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e3168 |
| SubjectTerms | AcrAB Adapter proteins Adjuvants Antibiotic resistance Antibiotic synergism Antibiotics Antimicrobial activity Antimicrobial agents Arginine Automation Bacteria Binding sites Cell death Cell division Chemotherapy Chlorpromazine Disease prevention Drug resistance E coli Efflux inhibitor Escherichia coli Ethidium bromide Fluorometry Gene expression Gram-negative bacteria Infectious Diseases Intracellular Membrane permeability Membrane potential Microbiology Minimum inhibitory concentration Multidrug resistance Mutation Permeability Protonmotive force RND Staphylococcus aureus Staphylococcus infections Toxicity |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBaGHopdhu5Zb1mhYbvs4CWRZEs-rkWLYECGpWiw3Aw9GxeBk-UBbP9-pOwEyRBgl94MiTZkkhI_mjRJyCfJ-xZ0xaWur1wqZOZhzzGdRjDLwP0JGj_oD7_ng7H4Nskme62-MCesKQ_cMK5bSKO0YI4rqwSTzqheKJTzBgYDD9HxATO250zFMxhQM4CLph6pBJelu_B--fAF2zQdWKBYqP8Yuvw3SXLP6tyckWctXKRfm2U-J098_YKcDtuA-EvyE3uZ0Xmgzf8JeAWIjrIUU7f-zH5tqhq78njqQ5htftOqnlYGNvGS_hiNxC3V97oCgEivVyi8ChOfKahG9YqMb67vrgZp2yshtYLn61QbFjBmB4iOu5BrFZwDZMW4EeD0OR-yAKbIZJnhhVfO5MJYKQs06EoHpflrclLPa39OKECyoPu5cyozQoNJt8LCTX3rnQw2Ywn5vOVfadtC4tjPYlaCQ4G8LiOvS-R1Qj7uaBdN-YyjVJcohh0FlryOA6AIZasI5f8UISGdrRDLdh-uSgwSckxlzRPyYTcNOwjDIrr28w3SxPhikcMj3jQy362EASAFSMgTIg-04WCphzN1NY1VujPBORyIbx_j3d6RpwzhRE-kLO-Qk_Vy498DGFqbi6j3fwEQeAok priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VrYS4IN6EFmQEFw6mje0kzgEhiraqkLpqKyp6i-zYboNWyXa7K5V_z0xesKjiFiVOZM3D89kzmQ_gfSbjEm3FcRdrx1WWePQ5YXgLZgVuf4KhA_3jWXp0rr5dJBdbMBv-haGyymFNbBdq15R0Rr5H6R5JRYnp58U1J9Yoyq4OFBqmp1Zwn9oWY_dgWxCr8gS2D6azk7Px1AUDXoqgo-tTmuFWZm_h_fLnR6Jv2ohMbQP_u1Dnv8WTf0Wjw0fwsIeR7Eun98ew5esncP-4T5Q_hR_EccaawLr_FugKkR4TnEq6fs2v11VNbD2e-RDm61tW1VeVRedespPTU3XGzKWpEDiy6Q0ptaKCaIYmUz2D88Pp969HvOdQ4KWS6YobKwLl8hDpSRdSo4NziLiEtCRK50MSMETZJLEy99rZVNkyy3IK9NoEbeRzmNRN7V8CQ6gWTJw6pxOrDIb6UpX4Ulx6l4UyERF8GORXlH2DceK5mBe40SBZF62sC5J1BO_GsYuurcadow5IDeMIaoXd3miWl0XvWUWeWW2UcDgfrUTmrN4PuXbe4s0gQxzB7qDEovfPm-KPNUXwdnyMnkXpElP7Zk1j2rxjnuInXnQ6H2ciEKgiVJQRZBvWsDHVzSd1ddV2706UlLhQvvr_tHbggSAAsa-4SHdhslqu_WuEPyv7prfp304iB5Q priority: 102 providerName: ProQuest |
| Title | Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against Escherichia coli |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28516003 https://www.proquest.com/docview/1953314106 https://www.proquest.com/docview/1900122961 https://pubmed.ncbi.nlm.nih.gov/PMC5433425 https://doaj.org/article/97b8a42d38c8427db80f98deba42f3f1 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: KQ8 dateStart: 20130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: DIK dateStart: 20130101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: GX1 dateStart: 20130101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: RPM dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2167-8359 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: BENPR dateStart: 20130212 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2167-8359 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000826083 issn: 2167-8359 databaseCode: M48 dateStart: 20131101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBddC2Mvo_v22gWNjcEenMWSbMlPYx3pyiClLQvLm5EsqfUITuIm0P73u5OdsJQ87MUYSbbF6U73O935jpCPkicl8IqNbaJsLGTqQOaYjgOYZWD-eI0H-qPz7Gwsfk7SyR5ZB7F3BLzdadphPalxM-3fLe6_gsADfu1LsEa-zJ1r_vSxAtOn-SLGglLoeO2qazwiB6CkGDL8qEP-YZMGWD0ISToZZv4GHJK3yUsfvHFLXYWs_rug6MOIyn9U1OkhedphS_qtZYZnZM_Vz8njUec9f0F-Y-EzOvO0_ZkB7wD-URZjnNf9dLGqaizh46jzfrq6o1V9UxmQ-IZeXF6KK6qvdQVokg5vcaUrjJKmwEfVSzI-Hf76fhZ3hRXiUvBsGWvDPDr4AP5x6zOtvLUAwxg3AixE63zqQW-ZNDU8d8qaTJhSyhy1v9Jeaf6K7Nez2r0hFPCb10lmrUqN0KD_S1HCQ0nprPRlyiLyeU2_ouyyjmPxi2kB1gfSugi0LpDWEfmwGTtvc23sHHWCy7AZgfmxQ8OsuS46cStyaZQWzMJ8lGDSGjXwubLOQKPnPonI8XoRizXPFehR5Bj3mkXk_aYbxA19KLp2sxWOCc7IPINXvG7XfDMTBugV8COPiNzihq2pbvfU1U1I6Z0KzmH3fPsf3z0iTxhCi4GIWXZM9pfNyr0DYLQ0PXJwMjy_uOqFgwW4_pgkvcD2fwFvyhJ6 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VVgIuiDeBAkbAgUNoYzuvQ4UobLWl3VVbtaK3YMd2G7RKtvsQ9M_x25hJsoFFFbfeosRJrPHM-LNnPB_Am1gEOeqK8U2QGF_GoUWb48qvwSzH5Y9TtKE_GEb9E_nlNDxdgV-LszCUVrnwibWjNlVOe-QbFO4RlJQYfRhf-MQaRdHVBYWGaqkVzFZdYqw92LFnL3_gEm66tfsZx_st5zu94099v2UZ8HMpopmvNHcU7UIsJIyLVOKMQUzChaafGetCh05ch6EWqU2MjqTO4zilqTBRLlECv3sD1hB2CLSqte3e8OCo2-XBCTZCkNPURY1x6bQxtnby_T3RRS3NhDVhwFUo999kzb9mv527cKeFrexjo2f3YMWW9-HmoA3MP4CvxKnGKseacxJ0hciScZ9SyC5HF_OiJHYgy6xzo_lPVpTnhUZnMmEHh4fyiKkzVSBQZb0pKVFBCdgMVbR4CCfXIs1HsFpWpX0CDKGhU0FkTBJqqRBa5DLHl4LcmtjlIffg3UJ-Wd4WNCdejVGGCxuSdVbLOiNZe_C6aztuynhc2WqbhqFrQaW36xvV5CxrLTlLY50oyQ32J5E8NjrZdGlirMabTrjAg_XFIGatP5hmf7TXg1fdY7RkCs-o0lZzalPHOdMIP_G4GfOuJxyBMUJT4UG8pA1LXV1-UhbndbXwUAqBjvnp_7v1Em71jwf72f7ucO8Z3OYEXjalz6N1WJ1N5vY5Qq-ZftHqN4Nv121SvwG3yEQv |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrVRxQbxZKGAEHDiEbWzndagQpbtqKV1tKyp6S-3YboNW2e0-BP2L_Cpmst7Aoopbb1HiJNZ4ZvzZM54P4E0iwgJ1xQQmTE0gk8iizXEV1GCW4_LHKdrQP-zHeyfy82l0uga_lmdhKK1y6RNrR21GBe2RdyjcIygpMe44nxYx2O19GF8GxCBFkdYlnYbyNAtmuy435g95HNirH7icm27v7-LYv-W81_36aS_wjANBIUU8C5TmjiJfiIuEcbFKnTGIT7jQ9GNjXeTQoeso0iKzqdGx1EWSZDQtpsqlSuB3b8F6QudFW7C-0-0PjpsdH5xsYwQ8ixqpCS6jOmNrJ9_fE3XUyqxYkwdch3j_Tdz8aybs3YU7HsKyjwuduwdrtroPG4c-SP8AvhG_Ghs5tjgzQVeIMhkPKJ3sang5LytiCrLMOjec_2RldVFqdCwTNjg6ksdMnasSQSvrTkmhSkrGZqiu5UM4uRFpPoJWNarsE2AIE50KY2PSSEuFMKOQBb4UFtYkroh4G94t5ZcXvrg5cWwMc1zkkKzzWtY5yboNr5u240VJj2tb7dAwNC2oDHd9YzQ5z71V51miUyW5wf6kkidGp1suS43VeNMJF7ZhczmIufcN0_yPJrfhVfMYrZpCNaqyozm1qWOeWYyfeLwY86YnHEEywlTRhmRFG1a6uvqkKi_qyuGRFAKd9NP_d-slbKBp5V_2-wfP4DYnHLMlAx5vQms2mdvniMJm-oVXbwZnN21RvwGgvUhp |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mode+of+action+of+the+2-phenylquinoline+efflux+inhibitor+PQQ4R+against+Escherichia+coli&rft.jtitle=PeerJ+%28San+Francisco%2C+CA%29&rft.au=Machado%2C+Diana&rft.au=Fernandes%2C+Laura&rft.au=Costa%2C+Sofia+S&rft.au=Cannalire%2C+Rolando&rft.date=2017-04-26&rft.issn=2167-8359&rft.eissn=2167-8359&rft.volume=5&rft.spage=e3168&rft_id=info:doi/10.7717%2Fpeerj.3168&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2167-8359&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2167-8359&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2167-8359&client=summon |